Neurocrine Biosciences Inc
NBIX
NBIX: Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
moreShow NBIX Financials
All
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of NBIX by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by NBIX's directors and management
Government lobbying spending instances
-
$780,000 Jul 20, 2023 Issue: Taxation/Internal Revenue Code Budget/Appropriations Health Issues Medicare/Medicaid
-
$780,000 Apr 20, 2023 Issue: Taxation/Internal Revenue Code Budget/Appropriations Health Issues Medicare/Medicaid
-
$700,000 Jan 20, 2023 Issue: Taxation/Internal Revenue Code Budget/Appropriations Health Issues Medicare/Medicaid
-
$790,000 Oct 20, 2022 Issue: Taxation/Internal Revenue Code Budget/Appropriations Health Issues Medicare/Medicaid
-
$790,000 Jul 20, 2022 Issue: Taxation/Internal Revenue Code Budget/Appropriations Health Issues Medicare/Medicaid
-
$900,000 Jun 13, 2022 Issue: Taxation/Internal Revenue Code Budget/Appropriations Health Issues Medicare/Medicaid
-
$730,000 Jun 13, 2022 Issue: Taxation/Internal Revenue Code Budget/Appropriations Health Issues Medicare/Medicaid
-
$720,000 Oct 20, 2021 Issue: None
-
$700,000 Jul 20, 2021 Issue: None
-
$590,000 Apr 20, 2021 Issue: None
-
$820,000 Jan 19, 2021 Issue: None
-
$480,000 Oct 19, 2020 Issue: None
-
$440,000 Jul 20, 2020 Issue: None
-
$440,000 Apr 20, 2020 Issue: None
-
$640,000 Jan 21, 2020 Issue: None
-
$60,000 Oct 21, 2019 Issue: Pharmacy
-
$60,000 Jul 22, 2019 Issue: Pharmacy
-
$60,000 Apr 22, 2019 Issue: Pharmacy
-
$60,000 Jan 22, 2019 Issue: Pharmacy
-
$60,000 Oct 22, 2018 Issue: Pharmacy
-
$60,000 Jul 20, 2018 Issue: Pharmacy
-
$60,000 Apr 20, 2018 Issue: Pharmacy
-
$60,000 Jan 22, 2018 Issue: Pharmacy
-
$60,000 Oct 20, 2017 Issue: Pharmacy
-
$60,000 Jul 20, 2017 Issue: Pharmacy
-
$10,000 Apr 24, 2017 Issue: Pharmacy
U.S. Patents
New patents grants
-
Patent Title: Treatment of congenital adrenal hyperplasia Aug. 22, 2023
-
Patent Title: Substituted pyrido[2,1-a]isoquinolines as vmat2 inhibitors Aug. 08, 2023
-
Patent Title: Gonadotropin-releasing hormone receptor antagonists and methods relating thereto Aug. 01, 2023
-
Patent Title: Methods for the administration of certain vmat2 inhibitors May. 23, 2023
-
Patent Title: Processes for the preparation of uracil derivatives Oct. 04, 2022
-
Patent Title: Methods for the administration of certain vmat2 inhibitors Sep. 13, 2022
-
Patent Title: Treatment of congenital adrenal hyperplasia Apr. 26, 2022
-
Patent Title: High dosage valbenazine formulation and compositions, methods, and kits related thereto Apr. 26, 2022
-
Patent Title: [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto Jul. 06, 2021
-
Patent Title: Vmat2 inhibitor compounds and compositions thereof Jun. 22, 2021
-
Patent Title: Methods for the administration of certain vmat2 inhibitors Jun. 22, 2021
-
Patent Title: Compounds of formulas (vii), (viii), (ix), (xi), (xii), (xiii), and (xiv) as muscarinic receptor 4(m4) antagonists for treating neurological diseases Jun. 15, 2021
-
Patent Title: High dosage valbenazine formulation and compositions, methods, and kits related thereto Jun. 08, 2021
-
Patent Title: Methods for the administration of certain vmat2 inhibitors Jun. 08, 2021
-
Patent Title: Substituted triazoles and methods relating thereto Jun. 01, 2021
-
Patent Title: Methods for the administration of certain vmat2 inhibitors May. 04, 2021
-
Patent Title: Methods for the administration of certain vmat2 inhibitors Mar. 23, 2021
-
Patent Title: Gonadotropin-releasing hormone receptor antagonists and methods relating thereto Mar. 09, 2021
-
Patent Title: Methods for the administration of certain vmat2 inhibitors Mar. 09, 2021
-
Patent Title: Synthetic methods for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) Feb. 16, 2021
-
Patent Title: Methods for the administration of certain vmat2 inhibitors Feb. 09, 2021
-
Patent Title: Synthetic methods for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1,-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) Feb. 02, 2021
-
Patent Title: Synthetic methods for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1,-a]isoquinolin-2-2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) Feb. 02, 2021
-
Patent Title: Treatment of congenital adrenal hyperplasia Feb. 02, 2021
-
Patent Title: Methods for the administration of certain vmat2 inhibitors Dec. 29, 2020
-
Patent Title: Methods for the administration of certain vmat2 inhibitors Dec. 08, 2020
-
Patent Title: Methods for the administration of certain vmat2 inhibitors Dec. 08, 2020
-
Patent Title: Valbenazine salts and polymorphs thereof Dec. 01, 2020
-
Patent Title: Valbenazine salts and polymorphs thereof Dec. 01, 2020
-
Patent Title: Valbenazine salts and polymorphs thereof Nov. 24, 2020
-
Patent Title: Substituted triazoles and methods relating thereto Aug. 11, 2020
-
Patent Title: Processes for the preparation of uracil derivatives Dec. 03, 2019
-
Patent Title: Gonadotropin-releasing hormone receptor antagonists and methods relating thereto Jul. 02, 2019
-
Patent Title: Substituted triazoles and methods relating thereto Nov. 27, 2018
-
Patent Title: Valbenazine salts and polymorphs thereof Sep. 04, 2018
-
Patent Title: [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto Jun. 05, 2018
-
Patent Title: Processes for the preparation of uracil derivatives Jan. 16, 2018
-
Patent Title: Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof Oct. 10, 2017
-
Patent Title: Substituted triazoles and methods relating thereto Aug. 01, 2017
-
Patent Title: [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto Jul. 25, 2017
-
Patent Title: Gonadotropin-releasing hormone receptor antagonists and methods relating thereto Aug. 23, 2016
-
Patent Title: Gonadotropin-releasing hormone receptor antagonists and methods relating thereto Feb. 10, 2015
-
Patent Title: Processes for the preparation of uracil derivatives Jul. 01, 2014
-
Patent Title: Gonadotropin-releasing hormone receptor antagonists and methods relating thereto Aug. 13, 2013
-
Patent Title: Gonadotropin-releasing hormone receptor antagonists and methods relating thereto Jul. 09, 2013
-
Patent Title: Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto Jan. 22, 2013
-
Patent Title: Gonadotropin-releasing hormone receptor antagonists and methods relating thereto Sep. 11, 2012
-
Patent Title: Gonadotropin-releasing hormone receptor antagonists and methods relating thereto Dec. 27, 2011
-
Patent Title: Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto Oct. 18, 2011
-
Patent Title: Crf receptor antagonists and methods relating thereto Jan. 26, 2010
Government Contracts
Federal grants, loans, and purchases
- $14,052 2021-12-01 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $677,822 2021-10-19 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $677,822 2021-09-29 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $674,516 2021-09-10 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $677,822 2021-09-08 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $653,022 2021-08-19 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $677,822 2021-08-04 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $677,822 2021-07-28 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $677,822 2021-07-13 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $542,257 2021-07-01 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $694,243 2021-05-14 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $697,550 2021-04-21 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $697,550 2021-04-07 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $658,644 2021-03-25 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $626,900 2021-03-05 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $14,052 2021-02-19 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $650,709 2021-02-17 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $449,677 2021-02-08 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $650,709 2021-01-07 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $43,479 2021-01-04 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $217,459 2020-12-29 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $608,584 2020-12-10 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $630,481 2020-11-19 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $652,376 2020-11-03 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $676,205 2020-10-08 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $543,648 2020-09-22 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $42,263 2020-09-14 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $608,584 2020-08-25 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $652,378 2020-08-06 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $420,321 2020-07-30 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $677,547 2020-06-23 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $579,766 2020-06-09 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $529,050 2020-05-19 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $405,723 2020-04-21 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $434,918 2020-04-10 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $576,116 2020-03-26 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $405,723 2020-03-10 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $536,349 2020-02-27 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $468,217 2019-12-11 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $807,062 2019-11-26 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $7,804 2019-11-15 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $403,531 2019-11-13 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $11,705 2019-11-12 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $497,175 2019-06-06 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $497,175 2019-05-08 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $497,175 2019-04-18 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $5,116 2019-04-03 00:00:00 Agency: DEPARTMENT OF JUSTICE (DOJ)
- $825,647 2019-02-21 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $605,297 2019-01-02 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $35,907 2018-10-17 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
Twitter
Followers on NBIX's company Twitter account
WallStreetBets
Number of mentions of NBIX in WallStreetBets Daily Discussion
NBIX News
Recent insights relating to NBIX
CNBC Recommendations
Recent picks made for NBIX stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in NBIX
Corporate Flights
Flights by private jets registered to NBIX